Dianthus Therapeutics (NASDAQ:DNTH) CAO Sells $3,559,646.18 in Stock

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) CAO Edward Carr sold 43,682 shares of the business’s stock in a transaction dated Thursday, March 12th. The stock was sold at an average price of $81.49, for a total value of $3,559,646.18. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Dianthus Therapeutics Stock Performance

Shares of NASDAQ DNTH opened at $77.86 on Monday. The business’s 50-day simple moving average is $52.53 and its 200-day simple moving average is $42.82. Dianthus Therapeutics, Inc. has a 52 week low of $13.36 and a 52 week high of $88.02. The firm has a market cap of $3.46 billion, a price-to-earnings ratio of -18.99 and a beta of 1.56.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its earnings results on Monday, March 9th. The company reported ($1.43) earnings per share for the quarter, missing the consensus estimate of ($0.97) by ($0.46). The company had revenue of $0.57 million during the quarter, compared to analyst estimates of $0.40 million. Dianthus Therapeutics had a negative return on equity of 38.85% and a negative net margin of 7,973.33%. As a group, equities research analysts forecast that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the stock. TD Cowen reaffirmed a “buy” rating on shares of Dianthus Therapeutics in a report on Monday, March 9th. Raymond James Financial upgraded shares of Dianthus Therapeutics from an “outperform” rating to a “strong-buy” rating and lifted their target price for the stock from $63.00 to $123.00 in a report on Tuesday, March 10th. Robert W. Baird boosted their target price on shares of Dianthus Therapeutics from $67.00 to $132.00 and gave the stock an “outperform” rating in a research report on Tuesday, March 10th. Jefferies Financial Group set a $98.00 price target on Dianthus Therapeutics and gave the company a “buy” rating in a research report on Monday, March 9th. Finally, Wedbush lifted their price objective on Dianthus Therapeutics from $55.00 to $80.00 and gave the stock an “outperform” rating in a research note on Tuesday, March 10th. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Dianthus Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $115.33.

Key Dianthus Therapeutics News

Here are the key news stories impacting Dianthus Therapeutics this week:

• Positive Sentiment: Company news: management announced an early Phase‑3 “go” decision and an upsized capital raise that sparked the recent rally; market reaction was enthusiastic because the program advancement de‑risked the story while the raise funds development and operations. Dianthus Therapeutics (DNTH) Is Up 30.8% After Upsized Raise And Early Phase 3 “Go” Decision
• Positive Sentiment: Financing closed: Dianthus completed an upsized underwritten offering that generated roughly $719M of gross proceeds (including full exercise of the underwriters’ option), strengthening the company’s cash runway for clinical work. This is a clear near‑term liquidity positive for investors. Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering…
• Positive Sentiment: Analyst upgrades: multiple firms (Raymond James, Wedbush, Robert W. Baird) issued bullish notes or raised their stance, which helped lift sentiment and trading activity. Upgrades add distribution and can attract momentum buyers. Dianthus Therapeutics (NASDAQ:DNTH) Raised to “Strong-Buy” at Raymond James Financial
• Positive Sentiment: Trading flow: the stock saw a large volume increase after analyst coverage/bullish headlines, indicating active repositioning by investors around the financing and clinical update. Higher volume can amplify price moves in either direction. Dianthus Therapeutics (NASDAQ:DNTH) Sees Large Volume Increase Following Analyst Upgrade
• Neutral Sentiment: Short-interest note: the most recent short‑interest data reported an anomalous zero‑share figure and essentially a 0.0 days‑to‑cover metric — likely a reporting quirk rather than a meaningful signal; treat with caution.
• Negative Sentiment: Analyst/model risk: HC Wainwright lowered near‑term and FY2026–FY2028 EPS forecasts substantially even while keeping a Buy rating and a high target; the cuts highlight expected cash burn and timing risk, which can pressure near‑term sentiment and invite profit‑taking.
• Negative Sentiment: Operational/financial backdrop: recent quarterly results included an EPS miss and very negative margins/returns, reminding investors that Dianthus remains a pre‑profit, high‑burn biotech—so upside is dependent on clinical progress and successful use of the new capital.

Institutional Investors Weigh In On Dianthus Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Patient Square Capital LP acquired a new position in Dianthus Therapeutics during the 3rd quarter valued at $4,919,000. Vanguard Group Inc. grew its position in Dianthus Therapeutics by 13.6% in the 3rd quarter. Vanguard Group Inc. now owns 1,642,198 shares of the company’s stock worth $64,620,000 after purchasing an additional 196,117 shares during the last quarter. XTX Topco Ltd acquired a new stake in Dianthus Therapeutics in the 2nd quarter worth $503,000. Sio Capital Management LLC increased its holdings in shares of Dianthus Therapeutics by 101.8% during the 2nd quarter. Sio Capital Management LLC now owns 236,070 shares of the company’s stock worth $4,398,000 after purchasing an additional 119,073 shares during the period. Finally, Ensign Peak Advisors Inc bought a new position in shares of Dianthus Therapeutics during the 2nd quarter worth about $2,504,000. Institutional investors and hedge funds own 47.53% of the company’s stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.